Facio expands portfolio with 100+ novel, chemically diverse DUX4 repressors

Monday, March 25, 2019

Facio Therapies announced that it has significantly expanded its portfolio of DUX4 repressors. After rigorous selection, Facio identified over 100 novel, chemically diverse small molecules that repress production of the human DUX4 protein in cultured FSHD-affected muscle cells. Facio is the only company known to have a pipeline of proprietary, chemically diverse small molecules that target the cause of FSHD.

Read more

Biotech Training Facility: unique professional GMP and biosafety courses in a state-of-the-art environment.

BTF